Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS

Nature Neuroscience

Volumn 8, Issue 1, 2005, Pages 85-92

  Storkebaum, Erik ^a   Lambrechts, Diether ^a   Dewerchin, Mieke ^a   Moreno Murciano, Maria Paz ^a   Appelmans, Saskia ^a   Oh, Hideyasu ^a   Van Damme, Philip ^b   Rutten, Bart ^c   Man, WingYan ^a   De Mol, Maria ^a   Wyns, Sabine ^a   Manka, David ^a   Vermeulen, Kristel ^a   Van Den Bosch, Ludo ^b   Mertens, Nico ^a   Schmitz, Christoph ^c   Robberecht, Wim ^b   Conway, Edward M ^a   Collen, Désiré ^a   Moons, Lieve ^a   Carmeliet, Peter ^a   more..

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; RECOMBINANT VASCULOTROPIN; VASCULOTROPIN RECEPTOR; NEUROPROTECTIVE AGENT; RECOMBINANT PROTEIN; SOD1 G93A PROTEIN; SUPEROXIDE DISMUTASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, HUMAN; VASCULOTROPIN A;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; MOTOR NEURON DISEASE; MOTOR PERFORMANCE; NERVE DEGENERATION; NEUROMUSCULAR SYNAPSE; NEUROPROTECTION; NONHUMAN; PARALYSIS; PRIORITY JOURNAL; RAT; TRANSGENE; ANIMAL; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECT; GENETICS; HUMAN; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MOTONEURON; NERVE FIBER TRANSPORT; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; WISTAR RAT;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; AXONAL TRANSPORT; CELL SURVIVAL; DISEASE MODELS, ANIMAL; HUMANS; INJECTIONS, INTRAVENTRICULAR; MOTOR NEURONS; NERVE DEGENERATION; NEUROMUSCULAR JUNCTION; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECOMBINANT PROTEINS; SUPEROXIDE DISMUTASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 16644382257     PISSN: 10976256     EISSN: None     Source Type: Journal    
DOI: 10.1038/nn1360     Document Type: Article

References (33)

1. Przedborski, S., Mitsumoto, H. & Rowland, L.P. Recent advances in amyotrophic lateral sclerosis research. Curr. Neurol. Neurosci. Rep. 3, 70-77 (2003).
2. Brown, R.H. Jr. & Robberecht, W. Amyotrophic lateral sclerosis: pathogenesis. Semin. Neurol. 21, 131-139 (2001).
3. Rothstein, J.D. Of mice and men: reconciling preclinical ALS mouse studies and human clinical trials. Ann. Neurol. 53, 423-426 (2003).
4. Gurney, M.E. et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264, 1772-1775 (1994).
5. Howland, D.S. et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc. Natl. Acad. Sci. USA 99, 1604-1609 (2002).
6. Nagai, M. et al. Rats expressing human cytosolic copper-zinc Superoxide dismutase transgenes with amyotrophic lateral sclerosis: associated mutations develop motor neuron disease. J. Neurosci. 21, 9246-9254 (2001).
7. Ferrara, N., Gerber, H.P. & LeCouter, J. The biology of VEGF and its receptors. Nat. Med. 9, 669-676 (2003).
8. Oosthuyse, B. et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat. Genet. 28, 131-138 (2001).
9. Lambrechts, D. et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat. Genet. 34, 383-394 (2003).
10. Storkebaum, E. & Carmeliet, P. VEGF: a critical player in neurodegeneration. J. Clin. Invest. 113, 14-18 (2004).
11. Azzouz, M. et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 429, 413-417 (2004).
12. Thoenen, H. & Sendtner, M. Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches. Nat. Neurosci. 5 (Suppl.), 1046-1050 (2002).
13. Kaspar, B.K., Llado, J., Sherkat, N., Rothstein, J.D. & Gage, F.H. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301, 839-842 (2003).
14. G93A G1H mouse model of familial amyotrophic lateral sclerosis. Brain Res. 982, 92-97 (2003).
15. G93A murine amyotrophic lateral sclerosis. Cytokine 23, 108-118 (2003).
16. Ramer, M.S., Bradbury, E.J., Michael, G.J., Lever, I.J. & McMahon, S.B. Glial cell line-derived neurotrophic factor increases calcitonin gene-related peptide immunoreactivity in sensory and motoneurons in vivo. Eur. J. Neurosci. 18, 2713-2721 (2003).
17. Raoul, C. & Aebischer, P. ALS, IGF-1 and gene therapy: 'it's never too late to mend'. Gene Ther. 11, 429-430 (2004).
18. Windebank, A.J. Use of growth factors in the treatment of motor neuron diseases. Adv. Neurol. 68, 229-234 (1995).
19. Thorne, R.G. & Frey, W.H. II Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin. Pharmacokinet. 40, 907-946 (2001).
20. Ouary, S. et al. Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for neuroprotection studies. Neuroscience 97, 521-530 (2000).
21. Lino, M.M., Schneider, C. & Caroni, P. Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. J. Neurosci. 22, 4825-4832 (2002).
22. Schafers, M., Geis, C., Brors, D., Yaksh, T.L. & Sommer, C. Anterograde transport of tumor necrosis factor-alpha in the intact and injured rat sciatic nerve. J. Neurosci. 22, 536-545 (2002).
23. Heerssen, H.M. & Segal, R.A. Location, location, location: a spatial view of neurotrophin signal transduction. Trends Neurosci. 25, 160-165 (2002).
24. Russell, F.D., Koishi, K., Jiang, Y. & McLennan, I.S. Anterograde axonal transport of glial cell line-derived neurotrophic factor and its receptors in rat hypoglossal nerve. Neuroscience 97, 575-580 (2000).
25. Watson, F.L. et al. Rapid nuclear responses to target-derived neurotrophins require retrograde transport of ligand-receptor complex. J. Neurosci. 19, 7889-7900 (1999).
26. D'Ercole, A.J., Ye, P. & O'Kusky, J.R. Mutant mouse models of insulin-like growth factor actions in the central nervous system. Neuropeptides 36, 209-220 (2002).
27. Ernfors, P., Lee, K.F. & Jaenisch, R. Mice lacking brain-derived neurotrophic factor develop with sensory deficits. Nature 368, 147-150 (1994).
28. Airaksinen, M.S. & Saarma, M. The GDNF family: signalling, biological functions and therapeutic value. Nat. Rev. Neurosci. 3, 383-394 (2002).
29. Giess, R. et al. Early onset of severe familial amyotrophic lateral sclerosis with a SOD-1 mutation: potential impact of CNTF as a candidate modifier gene. Am. J. Hum. Genet. 70, 1277-1286 (2002).
30. Gao, W.Q. et al. IGF-1 deficient mice show reduced peripheral nerve conduction velocities and decreased axonal diameters and respond to exogenous IGF-1 treatment. J. Neurobiol. 39, 142-152 (1999).
31. Orrell, R.W., King, A.W., Lane, R.J. & de Belleroche, J.S. Investigation of a null mutation of the CNTF gene in familial amyotrophic lateral sclerosis. J. Neurol. Sci. 132, 126-128 (1995).
32. Luttun, A. et al. Revascularization of ischemic tissues by PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat. Med. 8, 831-840 (2002).
33. Caroni, P., Schneider, C., Kiefer, M.C. & Zapf, J. Role of muscle insulin-like growth factors in nerve sprouting: suppression of terminal sprouting in paralyzed muscle by IGF-binding protein 4. J. Cell. Biol. 125, 893-902 (1994).